Clinical Trials Logo
  1. Home
  2. PD-1 Antibody
  3. NCT04944511

PD-1 Antibody Improve Mixed Chimerism — HLH  

PD-1 Antibody Clinical Trial

Official title:
PD-1 Antibody Improve Mixed Chimerism in Patients With Hemophagocytic Lymphohistiocytosis After Allo-HCT

Clinical Trial Summary

PD-1/PD-L1 pathway play an important role in Inhibiting the function of antigen-specific CD8+T cells, thus matter a lot in immune escape. We intend to use PD-1 antibody to improve the function of lymhocyte and improve the chimerism in patients after allo-HCT.

Clinical Trial Description

Mixed chimerism is a trouble condition after allogeneic hematopoietic cell transplantation (Allo-HCT),all targeted treatment are aimed to improve the function of lymphocyte recipient. PD-1 antibody was reported to restored the function of impaired lymphocyte. Therefore, we want to use PD-1 antibody to improve the function of lymhocyte and improve the chimerism in HLH patients after allo-HCT. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04944511
Study type Interventional
Source Beijing Friendship Hospital
Contact Zhao Wang
Phone 86-010-63139862
Email wangzhao@ccmu.edu.cn
Status Not yet recruiting
Phase N/A
Start date July 1, 2021
Completion date May 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT04507217 - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC Phase 2
Not yet recruiting NCT04108013 - A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC Phase 2
Active, not recruiting NCT03668496 - A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC Phase 3
Not yet recruiting NCT04834674 - DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma Phase 2
Not yet recruiting NCT05461235 - Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma Phase 2
Not yet recruiting NCT03777124 - Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer Phase 2
Active, not recruiting NCT05156788 - Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer Phase 2
Recruiting NCT02862028 - PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach) Phase 1/Phase 2
Recruiting NCT02873390 - PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor Phase 1/Phase 2
Recruiting NCT05554276 - Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer Phase 2
Not yet recruiting NCT05775705 - L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH Phase 3